Rubicon Research Q2 FY27 Revenue Jumps 39.9% to ₹576.4 Crore; EBITDA Up 54.1%
Rubicon Research reported Q2 FY27 revenue of ₹576.4 crore, a 39.9% YoY increase. EBITDA rose 54.1% to ₹146.4 crore, and PAT grew 67.9% to ₹90.4 crore. The company raised its FY27 EBITDA margin guidance to over 24%. Q2 USD revenue was $58 million, up 5%+ sequentially. Three new product approvals were received.
Significant growth in key financial metrics and an upward revision of guidance are material positive developments for investors, likely to impact the stock price.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with an upward revision of its EBITDA margin guidance, indicating positive financial performance and outlook.
Rubicon Research Limited announced its financial results for the second quarter of FY 2026-27, reporting a significant 39.9% year-on-year increase in revenue from operations, reaching ₹5,764 million (₹576.4 crore). The company's EBITDA also saw a substantial rise of 54.1% to ₹1,464 million (₹146.4 crore), with EBITDA margins improving to 25.4% from 23.1% in the same period last year. Profit After Tax (PAT) grew by 67.9% to ₹904 million (₹90.4 crore), and Earnings Per Share (EPS) increased by 56.2% to ₹5.41.
The company also revised its Operating EBITDA Margin guidance for FY27 upwards to 24%+, from the previously guided 23%+. For the first half of FY27, revenue from operations stood at ₹11,107 million (₹1,110.7 crore), up 45.3% year-on-year, with cash flow from operations at ₹989 million (₹98.9 crore).
Rubicon Research highlighted that its Q2 FY27 numbers include the impact of consolidation following the Arinna acquisition. The company received three product approvals in Q2 FY27, maintaining a strong commercialization rate of 84% for approved products. Pricing has remained stable, driven by a focus on specialty and differentiated products. USD revenue for Q2 FY27 was $58 million, a 5%+ increase compared to $55 million in Q1 FY27.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.